Patent assignee · DE · COMPANY

CSL Behring AG

94Patents
86Active
94Granted
54Portfolio score

Filing activity: Mar 16, 2001 → Mar 18, 2022 · 28 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US7759315B2 Treatment of inflammatory conditions of the intestine Human Necessities 88 Active
US7491197B2 Fluid transfer device Human Necessities 84 Expired
US8172824B2 Apparatus for combining components under sterile conditions Human Necessities 60 Expired
US8283319B2 Therapeutic application of Kazal-type serine protease inhibitors Human Necessities 30 Active
US7939632B2 Proteolytically cleavable fusion proteins with high molar specific activity Chemistry; Metallurgy 26 Active
US8632773B2 Antibody composition with altered Fab sialylation Chemistry; Metallurgy 17 Active
US8715652B2 Immunoglobulin preparations having increased stability Human Necessities 15 Active
US8575104B2 Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life Chemistry; Metallurgy 14 Active
US7351561B2 Thrombin preparations and process for their production Human Necessities 13 Expired
US7572769B2 Fibrin adhesive granulate and method for its preparation Human Necessities 13 Active
US7335634B2 Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers Human Necessities 11 Expired
US10286047B2 Treatment and prevention of remote ischemia-reperfusion injury Chemistry; Metallurgy 9 Active
US8754194B2 Modified coagulation factors with prolonged in vivo half-life Chemistry; Metallurgy 9 Active
US7550567B2 Fibrinogen purification Human Necessities 9 Expired
US9522184B2 CD89 activation in therapy Chemistry; Metallurgy 7 Active
US8436152B2 Methods for purification of alpha-1-antitrypsin andapolipoprotein A-1 Chemistry; Metallurgy 7 Active
US8765915B2 Modified coagulation factor VIIa with extended half-life Chemistry; Metallurgy 7 Active
US8119137B2 Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII Emerging Cross-Sectional Technologies 6 Active
US8962802B2 Methods for purification of alpha-1-antitrypsin and apolipoprotein A-1 Chemistry; Metallurgy 6 Active
US9856326B2 Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies Chemistry; Metallurgy 6 Active
US7939288B2 Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques Chemistry; Metallurgy 6 Active
US9624307B2 Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs Physics 5 Active
US9347051B2 Coagulation factor X polypeptides with modified activation properties Chemistry; Metallurgy 5 Active
US9352016B2 Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces Chemistry; Metallurgy 5 Active
US7625866B2 Concentrate of a factor VIII:C-containing von Willebrand factor and the process relating thereto Human Necessities 5 Expired

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.